Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Papillomavirus Infections 1Atypical Squamous Cells of the Cervix 1

Interventions

pembrolizumab 302Carboplatin 230Cisplatin 159Paclitaxel 153Gemcitabine 153Pemetrexed 122Bevacizumab 121Docetaxel 105durvalumab 83Oxaliplatin 82Nivolumab 82Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 79130-nm albumin-bound paclitaxel 74Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 57fludarabine 52Lenalidomide 51venetoclax 47Prednisone 45Irinotecan 42enzalutamide 41Letrozole 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × epigallocatechin gallate × 90 days × Clear all
NCT07572396 2026-05-14

Phase II Study of Dysplasixâ„¢ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

Amplexd Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia, Papillomavirus Infections, Atypical Squamous Cells of the Cervix

Data powered by HemOnc (CC BY 4.0) Colophon âš¡